Literature DB >> 9430807

Failure of erythropoietin treatment in a case with primary autonomic failure.

L Keselbrener1, A Korzets, S Akselrod.   

Abstract

Previous studies have reported that anemia is a frequent occurrence in patients with severe autonomic failure, that it can be corrected by exogenous erythropoietin and that upright blood pressure improves while on erythropoietin. The objective of this study was to determine the alteration of autonomic control during erythropoietin therapy in a patient with severe autonomic failure and severe symptomatic orthostatic hypotension, evaluated by spectral analysis of heart rate variability. The autonomic response to standing was evaluated before, after 1 month and after 6 months of erythropoietin therapy. The results were compared to an age- and sex-matched control adult. There was no improvement in the orthostatic hypotension during and at the end of the erythropoietin treatment despite an increase in hemoglobin from 9.6 g/dl before treatment to 12.5 g/dl during treatment. The spectral estimates of heart rate variability displayed a low variability at baseline, a paradoxical vagal enhancement and a lack of sympathetic increase on standing (before, during and at the end of the treatment). There was no improvement of baseline activity, nor of the response to standing during and at the end of the treatment with erythropoietin. We conclude that erythropoietin did not improve the autonomic response to standing, although it corrected anemia. Erythropoietin did not alter sympathetic activity, as reflected in the low frequency content of the power spectrum of heart rate fluctuations during and at the end of treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430807     DOI: 10.1007/bf02267727

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  18 in total

1.  Selective discrete Fourier transform algorithm for time-frequency analysis: method and application on simulated and cardiovascular signals.

Authors:  L Keselbrener; S Akselrod
Journal:  IEEE Trans Biomed Eng       Date:  1996-08       Impact factor: 4.538

2.  Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine).

Authors:  H Kaufmann; T Brannan; L Krakoff; M D Yahr; J Mandeli
Journal:  Neurology       Date:  1988-06       Impact factor: 9.910

3.  Aging of modulation of heart rate.

Authors:  D C Shannon; D W Carley; H Benson
Journal:  Am J Physiol       Date:  1987-10

4.  Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control.

Authors:  S Akselrod; D Gordon; F A Ubel; D C Shannon; A C Berger; R J Cohen
Journal:  Science       Date:  1981-07-10       Impact factor: 47.728

5.  Hemodynamic regulation: investigation by spectral analysis.

Authors:  S Akselrod; D Gordon; J B Madwed; N C Snidman; D C Shannon; R J Cohen
Journal:  Am J Physiol       Date:  1985-10

6.  Clonidine raises blood pressure in severe idiopathic orthostatic hypotension.

Authors:  D Robertson; M R Goldberg; A S Hollister; D Wade; R M Robertson
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

7.  Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome.

Authors:  A Schirger; S G Sheps; J E Thomas; R D Fealey
Journal:  Mayo Clin Proc       Date:  1981-07       Impact factor: 7.616

8.  Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure.

Authors:  R Perera; L Isola; H Kaufmann
Journal:  Clin Auton Res       Date:  1995-09       Impact factor: 4.435

9.  Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension.

Authors:  B P Grubb; D Samoil; D Kosinski; D Wolfe; M Lorton; E Madu
Journal:  Am J Med       Date:  1994-10       Impact factor: 4.965

Review 10.  Management of chronic orthostatic hypotension.

Authors:  J Onrot; M R Goldberg; A S Hollister; I Biaggioni; R M Robertson; D Robertson
Journal:  Am J Med       Date:  1986-03       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.